In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Hold rating on HilleVax, Inc (HLVX – Research Report), with a price target of $2.00. Matthew Caufield has given his ...

HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company with a market capitalization of approximately $84 million, saw its Chief Financial Officer Shane Maltbie recently sell ...

HilleVax Inc.’s stock cratered 89% early Monday, after the biotech said it would discontinue development of a vaccine against norovirus for infants after a trial missed its main goals.

Get the latest HilleVax, Inc. (HLVX) stock news and headlines to help you in your trading and investing decisions.

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Hold rating on HilleVax, Inc (HLVX – Research Report). The associated price target remains the same with $2.00. Matthew Caufield ...

Shares of HilleVax plunged as much as 87.6% to a record low of $1.75 on Monday after the biotech company said it will discontinue the development of its norovirus vaccine candidate for infants.

Shares of HilleVax fell after the release of Phase 2b trial results for HIL-214, a vaccine for norovirus-related acute gastroenteritis in infants. The study showed 5% efficacy and no significant ...

The average of price targets set by Wall Street analysts indicates a potential upside of 67% in HilleVax, Inc. (HLVX). While the effectiveness of this highly sought-after metric is questionable ...

HilleVax announced three leadership positions have been filled Monday morning. The new hires include Ozzie Berger as SVP of regulatory affairs, Anju Chatterji being elevated to chief technical officer ...

HilleVax Inc.’s stock cratered 89% early Monday, after the biotech said it would discontinue development of a vaccine against norovirus for infants after a trial missed its main goals.